

ABBREVIATIONS

ARV antiretroviral	LEAP Long-acting extended-release Antiretroviral research resource Program
ART antiretroviral therapy	LEN lenacapavir
BIC bictegravir	LMIC low-to-middle income country
bNAb broadly neutralizing antibody	LPV lopinavir
CAB cabategravir	LTBI latent tuberculosis Infection
cART combination antiretroviral therapy	mAb monoclonal antibody
CHAI Clinton Health Access Initiative	MPP Medicines Patent Pool
CMC chemistry, manufacturing and controls	NHP non-human primate
COGS cost of goods sold	NRTI nucleoside reverse transcriptase inhibitor
DAA direct-acting antiviral	NRTTI nucleoside reverse transcriptase translocation inhibitor
DDI drug-drug interaction	OLI oral lead-in
DMPK drug metabolism & pharmacokinetics	PBPK physiologically based pharmacokinetics
DTG dolutegravir	PBMC peripheral blood mononuclear cell
ER extended-release	PD pharmacodynamics
FDA Food and Drug Administration	PEP post-exposure prophylaxis
FTC emtricitabine	PK pharmacokinetic
GLAD Global Long-Acting and Drug combination products	PLWH people living with HIV
GLP good laboratory practice	PrEP pre-exposure prophylaxis
GMP good manufacturing practice	RLS resource-limited setting
HBV hepatitis B Virus	RPV rilpivirine
HCV hepatitis C Virus	RTV ritonavir
HIV human immunodeficiency virus	SC subcutaneous
HPTN HIV Prevention Trials Network	SIV Simian immunodeficiency virus
IM intramuscular	TAF tenofovir alafenamide
INH isoniazid	TB tuberculosis
IMPAACT International Maternal Pediatric Adolescent AIDS Clinical Trials	TDF tenofovir disoproxil fumarate
INSTI integrase strand transfer inhibitor	TFV tenofovir
ISL islatravir	TLD tenofovir, lamivudine and dolutegravir
LA long-acting	
LAI long-acting injectable	